Scarica l'app Stockscreener
42.19
5.63%
2.25
Dopo l'orario di chiusura:
42.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$39.94
Aprire:
$40
Volume 24 ore:
4.27M
Relative Volume:
1.79
Capitalizzazione di mercato:
$7.03B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
46.91
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
+14.65%
1M Prestazione:
+25.16%
6M Prestazione:
+42.63%
1 anno Prestazione:
+39.47%
Intervallo 1D:
$39.64
$42.83
Intervallo di 1 settimana:
$36.49
$42.83
Portata 52W:
$25.16
$42.83
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
42.19 | 6.66B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
15.96 | 51.03B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.32 | 40.20B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.06 | 40.78B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.69 | 32.81B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
556.82 | 23.86B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes (ALKS) finance VP exercises options and sells 16,217 shares - Stock Titan
Alkermes Plc Hits New 52-Week High at $40.78, Up 65% - Markets Mojo
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences - MSN
Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat - AD HOC NEWS
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Alkermes stock hits 52-week high at 39.57 USD By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at 39.57 USD - Investing.com
Alkermes to showcase leadership in psychiatry and orexin biology with new data at the American Society of Clinical Psychopharmacology annual meeting - MSN
New orexin data on narcolepsy, schizophrenia at ASCP meeting - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Unlocking Potential With A 23.47% Upside - DirectorsTalk Interviews
Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants - Stock Titan
Alkermes (ALKS) director gets new RSUs, options and tax withholding - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
Alkermes (NASDAQ: ALKS) director reports RSU vesting, option grant and tax-share withholding - Stock Titan
[Form 4/A] Alkermes plc. Amended Insider Trading Activity - Stock Titan
Alkermes (ALKS) director receives equity awards and corrects vesting terms - Stock Titan
Alkermes (ALKS) director reports RSU vesting, tax withholding and new stock options - Stock Titan
Alkermes (NASDAQ: ALKS) director logs RSU exercise, new option and RSU grants - Stock Titan
Avoiding Lag: Real-Time Signals in (ALKS) Movement - Stock Traders Daily
Alkermes Shareholders Approve Amended Stock Incentive Plan - The Globe and Mail
LYBALVI data detail real-world relapse and ER visit outcomes - Stock Titan
Alkermes (ALKS) shareholders approve 2018 equity plan, directors and auditor - Stock Titan
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge - TipRanks
Alkermes plc (ALKS) Stock Analysis: Uncovering a 21% Upside Potential in Biopharmaceutical Innovation - DirectorsTalk Interviews
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes plc stock (IE00B56GVS15): M&A deal with Avadel and fresh analyst signals put focus on futur - AD HOC NEWS
Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures - AD HOC NEWS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline - TipRanks
T. Rowe Price (NASDAQ: ALKS) holds 4.66M shares, 2.8% stake - Stock Titan
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia - Sleep Review
What is HC Wainwright's Estimate for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc $ALKS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Alkermes stock hits 52-week high at $38.94 By Investing.com - Investing.com South Africa
Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48 - AD HOC NEWS
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alkermes reports encouraging data from Phase III study of Lumryz - Clinical Trials Arena
Alkermes stock hits 52-week high at $38.94 - Investing.com
ALKS Maintained by Baird -- Price Target Raised to $48.00 - GuruFocus
Alkermes (NASDAQ:ALKS) Price Target Raised to $48.00 - MarketBeat
Alkermes Gains Strength On Strong Execution And Strategic Diversification - RTTNews
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights
Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media
Alkermes posts late-stage trial win for Lumryz in new sleep disorder - MSN
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles - Benzinga
Investors Can Find Comfort In Alkermes' (NASDAQ:ALKS) Earnings Quality - 富途牛牛
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 - Quantisnow
Positive Phase 3 Results for Alkermes (ALKS) LUMRYZ in Treating Hypersomnia - GuruFocus
Alkermes (ALKS) Shares Rise on Positive Sleep Disorder Therapy T - GuruFocus
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alkermes Plc Azioni (ALKS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
May 29 '26 |
Sale |
42.36 |
16,217 |
687,007 |
7,717 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. |
May 04 '26 |
Sale |
33.20 |
2,034 |
67,529 |
231,558 |
0.81%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):